← FDA DRUG APPROVALS

FDA ANDA · ANDA219231

CARBIDOPA AND LEVODOPA

Sponsor: DR REDDYS LABS LTD

APPLICATION
ANDA219231
TYPE
ANDA
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
None (Tentative Approval)

Products

CARBIDOPA AND LEVODOPANone (Tentative Approval)
CARBIDOPA, LEVODOPA 195MG · CAPSULE, EXTENDED RELEASE
CARBIDOPA AND LEVODOPANone (Tentative Approval)
CARBIDOPA, LEVODOPA 61.25MG · CAPSULE, EXTENDED RELEASE
CARBIDOPA AND LEVODOPANone (Tentative Approval)
CARBIDOPA, LEVODOPA 95MG · CAPSULE, EXTENDED RELEASE
CARBIDOPA AND LEVODOPANone (Tentative Approval)
CARBIDOPA, LEVODOPA 145MG · CAPSULE, EXTENDED RELEASE
CARBIDOPA AND LEVODOPANone (Tentative Approval)
CARBIDOPA, LEVODOPA 48.75MG · CAPSULE, EXTENDED RELEASE
CARBIDOPA AND LEVODOPANone (Tentative Approval)
CARBIDOPA, LEVODOPA 245MG · CAPSULE, EXTENDED RELEASE
CARBIDOPA AND LEVODOPANone (Tentative Approval)
CARBIDOPA, LEVODOPA 23.75 · CAPSULE, EXTENDED RELEASE

Approval history

2025-06-13UNKNOWN · Original · standardTA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →